Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update ...

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients ...

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of ...

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., Jul ...

Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic ...

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy ...

The Grumbles family invites the community to celebrate the life and legacy of their late son, Luke, who would have been 18 on July 31, by donating blood. Luke Grumbles, 10, the son of Dwayne and ...

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...